Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline today and set a price target of £19.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 3.4% and a 51.83% success rate on recommended stocks.
In addition to Deutsche Bank , GlaxoSmithKline also received a Hold from Citi’s Graham Parry in a report issued on May 29. However, on June 3, Jefferies maintained a Buy rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p7.63 billion and a net profit of p1.74 billion. In comparison, last year the company earned a revenue of p7.52 billion and had a net profit of p1.62 billion
Based on the recent corporate insider activity of 330 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- Acting FDA head vows to block political interference, Endpoint News says
- FDA issues draft guidance to help accelerated cell, gene therapies for patients
- GSK boosts treasury stock as buyback lifts voting share base
- GSK Updates Market on Total Voting Rights and Share Capital
- GSK’s ViiV Healthcare launches PrEP Wisdom campaign
